The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management

European Journal of Health Economics

Volumn 8, Issue 2, 2007, Pages 97-103

  Bjegovic, Vesna ^a   Terzic, Zorica ^a   Marinkovic, Jelena ^a   Lalic, Nebojsa ^a   Sipetic, Sandra ^a   Laaser, Ulrich ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b BIELEFELD UNIVERSITY   (Germany)

Author keywords

Burden of disease; Clinical guidelines; Cost effectiveness; Diabetes mellitus; Serbia

Indexed keywords

ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; YUGOSLAVIA;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; YUGOSLAVIA;

EID: 34248377830     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0012-7     Document Type: Article

References (18)

1. Atanaskovic-Markovic, Z., Bjegovic, V., Jankovic, S., Kocev, N., Laaser, U., Marinkovic, J., Markovic-Denic, Lj., Pejin-Stokic Lj., Penev, g., Stanisavljevic, D., Santric-Milicevic, M., Saulic, A., Sipetic-Grujicic, S., Terzic-Supic, Z., Vlajinac, H.: The burden of disease and injury in Serbia. Ministry of Health, Belgrade (2003)
2. National Committee for Guidelines of Clinical Practice in Serbia, Diabetes mellitus (chair: Professor N. Lalic): National Serbian Guideline for Diabetes Mellitus (NSGDM). The European Agency for Reconstruction/EPOS Health Consultants, Belgrade. Serbian version, Prevencija tipa 2 Dijabetesa (2005). Beograd (2002), ISBN 86-85313-36-8
3. Murray, C.J.L., Lopez, A.D.: The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. The global burden of disease and injury series, vol 1. Harvard School of Public Health on Behalf of the World Health Organisation and The World Bank, Harvard University Press, Boston (1996)
4. Statistical yearbook of Serbia and Montenegro. The Statistical Office, Belgrade (2003)
5. Penev, G.: Mortality trends in Serbia during the 1990s. Stanovnistvo 41(1-4), 93-130 (2003)
6. The Belgrade registry of diabetes mellitus. Institute of Public Health of Belgrade, Belgrade (2004)
7. City Institute of Statistical Review of Health Services in Belgrade. City Institute of Public Health ,Belgrade (2000)
8. Russell, B., Valiyeva, E., Roman, S.H., Pogach, L.M., Suh, D.C., Safford, M.M.: Hospitalizations, nursing home admissions, and deaths attributable to diabetes. Diabetes Care 28, 1611-1617 (2005)
9. International Diabetes Federation (IDF).: Prevalence estimates of diabetes mellitus. Diabetes Atlas available from http://www.idf.org/eatlas/home/ index.cfm?unode=3B96ECBD-C026-2FD3-877530074C49FF55 accessed 24 March 2005 (2005)
10. Jönsson, B.: The economic impact of diabetes. Diabetes Care 21(Suppl. 3), C7-C10 (1998)
11. King, H., Aubert, R.E., Herman, W.H.: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21, 1414-1431 (1998)
12. Schmitt-Koopmann, I., Schwenkglenks, M., Spinas, G.A., Szucs, T.D.: Direct medical costs of type 2 diabetes and its complications in Switzerland. Eur J Public Health 14, 3-9 (2004)
13. Brandle, M., Burke, R., Zhou, H., Tabaei, B.P., Smith, B.R.K., Brown, M.B., Marriott, D.: The direct medical cost of type 2 diabetes. Diabetes Care 26, 2300-2304 (2003)
14. The Diabetes Prevention Program Research Group.: Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 26, 36-47 (2003)
15. Ragnarson, T.G., Apelqvist, J.: Prevention of diabetes-related foot-ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia 44, 2077-2087 (2001)
16. Ortegon, M.A., Redekop, W.K., Niessen, L.W.: Cost-effectiveness of prevention and treatment of the diabetic foot. Diabetes Care 27, 901-907 (2004)
17. The CDC Diabetes Cost-effectiveness Group.: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287, 2542-2551 (2002)
18. The Diabetes Prevention Program Research Group.: Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 26, 2518-2523 (2003)